In an era of increasing environmental consciousness, the pharmaceutical industry finds itself at a critical juncture. With the implementation of the EU's Corporate Sustainability Reporting Directive in January 2024, large pharmaceutical organisations are facing growing pressure to enhance their sustainability reporting practices. Our latest white paper, "Benchmarking Scope 3 Emissions Reporting Across the Pharmaceutical Industry," offers an in-depth exploration of this timely topic. The paper discusses the growing emphasis on addressing Scope 3 emissions and the trend towards more comprehensive reporting and adoption of science-based targets. Here's a glimpse of what you'll discover in our comprehensive analysis: Key Sustainability Frameworks and Initiatives shaping the pharmaceutical sector's approach to sustainability Industry-Wide Challenges and complexities of Scope 3 emissions reporting Comprehensive analysis of Scope 3 emissions data from the top 25 pharmaceutical and biotech org

March 21, 2023 The science is clear: Emissions need to fall 45% by 2030 to avoid the worst climate impacts. Limiting global warming to well below 2 degrees Celsius can avoid further impact on global health, according to the Intergovernmental Panel on Climate Change (IPCC). Healthcare stakeholders must play their part by accelerating the delivery of patient-centric, equitable, net zero health systems. As the latest report by the IPCC shows, this is no longer a challenge for tomorrow: we are already seeing the impacts today with increased incidence of events such as extreme heat, floods, and wildfires across the globe. We need to act urgently and reduce emissions globally to limit further global warming. The pharmaceutical industry has a significant impact on the environment due to the large quantities of energy, water, and raw materials required for drug manufacturing. As a result, there is growing pressure for pharmaceutical companies to embed environmental sustainability into their op